11:26 AM
 | 
Mar 01, 2019
 |  BioCentury  |  Emerging Company Profile

Siolta: Seeding the microbiome

How Siolta’s bacterial cocktail could prevent the onset of asthma in infants

Backed by Khosla Ventures and about a decade of research connecting the microbiome to allergic diseases, Siolta Therapeutics Inc. has its bacterial cocktail in a Phase I trial to prevent the onset of asthma in newborns along with a companion diagnostic for the disease.

Siolta co-founders Susan Lynch and Nikole Kimes met when Kimes joined Lynch’s lab as a postdoc at University of California San Francisco, where Lynch is an assistant professor of medicine.

“By the time I came, they had been doing work with clinical data to tease apart signals from gut microbiota from a child’s first months of life to predict risk of allergic diseases later in life,” said Kimes, who is Siolta’s president and CSO.

In a 2018 Nature Communications paper, Lynch’s lab found that the meconium microbiota of infants at a high risk for asthma had lower levels of...

Read the full 699 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >